IQVIA HOLDINGS INC. (IQV)
D
Pipeline Grade
Financial Position (from SEC Filings)
$1,947.0M
Cash & Equivalents
$618.0M
Quarterly Burn Rate
$27,642M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05267613 | Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. | PHASE3 | Active Not Recruiting | 53 |
| NCT06549946 | Ixovex-1 Single Agent and Combination Therapy | PHASE2 | Recruiting | 18 |
| NCT07517445 | Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susc... | PHASE2 | Recruiting | 165 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.